Epidemiology of Immunoglobulin Resistant Kawasaki Disease: Results from a Large, National Database
- 2 September 2014
- journal article
- Published by Springer Nature in Pediatric Cardiology
- Vol. 36 (2) , 374-378
Abstract
Few data exist evaluating the epidemiology of Kawasaki disease (KD) resistant to intravenous immunoglobulin (IVIG) in the United States on a national level, and characterization of the epidemiology of IVIG resistance may improve patient care. We aim to characterize the incidence of KD resistant to IVIG therapy and risk factors for resistance in children’s hospitals in the United States. A large, administrative database was used to identify pediatric patients admitted with an ICD-9 code for mucocutaneous lymph node syndrome (446.1) and a charge for at least one dose of IVIG. Patients were identified as resistant to IVIG therapy if there were ≥2 calendar days between an initial IVIG dose and a subsequent dose of IVIG, methylprednisolone, rituximab, or infliximab. Patient demographic and hospital information were collected, as well as the charges for imaging, laboratory, and medications. Resistance occurred in 16.3 % (hospital range 8.0–26.8 %) of the population and was not associated with time or number of patients admitted with KD. Patients admitted to hospitals in the highest quartile of resistance were more likely to be African-American (26.5 vs 20.1 %, p < 0.01), less likely to have an echocardiogram performed (93.6 vs 97.1 %, p < 0.01), were more likely to have a C-reactive protein drawn (93 vs 79.9 %, p < 0.01), and were less likely to have an erythrocyte sedimentation rate drawn (87.9 vs 91.6 %, p < 0.01). The incidence of KD resistant to IVIG is highly variable among pediatric hospitals and treatment patterns vary between hospitals with high- and low-resistance patterns. Further evaluation of diagnostic and treatment patterns at pediatric hospitals is warranted.Keywords
This publication has 14 references indexed in Scilit:
- Increased Incidence of Incomplete Kawasaki Disease at a Pediatric Hospital After Publication of the 2004 American Heart Association GuidelinesPediatric Cardiology, 2012
- Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective StudyThe Journal of Pediatrics, 2011
- External Validation of a Risk Score to Predict Intravenous Immunoglobulin Resistance in Patients With Kawasaki DiseaseThe Pediatric Infectious Disease Journal, 2011
- Assessment of intravenous immunoglobulin non-responders in Kawasaki diseaseArchives of Disease in Childhood, 2010
- Treatment of Kawasaki Disease: Analysis of 27 US Pediatric Hospitals From 2001 to 2006Pediatrics, 2009
- Resistance to Intravenous Immunoglobulin in Children with Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.2006
- The Epidemiology of Kawasaki Disease in an Urban Hospital: Does African American Race Protect Against Coronary Artery Aneurysms?Pediatric Cardiology, 2005
- Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart AssociationPediatrics, 2004
- Prediction of non-responsiveness to intravenous high-dose γ-globulin therapy in patients with Kawasaki disease at onsetThe Journal of Pediatrics, 2000